Landos Biopharma Inc
NASDAQ:LABP
| Market Cap (Intraday) | 477.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | N/A |
| 50-Day MA | N/A |
| 200-Day MA | N/A |
Landos Biopharma Inc Stock, NASDAQ:LABP
1800 Kraft Drive, Suite 216, Blacksburg, Virginia 24060
United States of America
Phone: +1.540.218.2232
Number of Employees: 33
Description
Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn�s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.